SUPERNUS PHARMACEUTICALS, INC. Accounts Receivable, Allowance for Credit Loss
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Accounts Receivable, Allowance for Credit Loss of $0 as of 2019-12-31, per its 10-K filed 2020-02-28.
Discontinued › Balance Sheet › Assets
us-gaap:AllowanceForDoubtfulAccountsReceivable · last filed 2020-02-28
- 2019-12-31: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2018-12-31: Accounts Receivable, Allowance for Credit Loss $100.00K.
- 2018-09-30: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2018-06-30: Accounts Receivable, Allowance for Credit Loss $0.00.
| Period end | Accounts Receivable, Allowance for Credit Loss | Accounts Receivable, Allowance for Credit Loss as first filed |
|---|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-02-28 | |
| 2018-12-31 | $100.00K 10-K · filed 2020-02-28 | |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $0.00 10-K · filed 2020-02-28 | |
| 2017-03-31 | $0.00 10-Q · filed 2018-05-10 | |
| 2016-12-31 | $400.00K 10-K · filed 2019-03-01 | $42.00K 10-K · filed 2017-03-16 |
| 2016-09-30 | $38.00K 10-Q · filed 2017-01-20 | |
| 2016-06-30 | $100.00K 10-Q/A · filed 2017-01-23 | |
| 2015-12-31 | $0.00 10-K/A · filed 2017-01-20 | |
| 2014-12-31 | $0.00 10-K/A · filed 2017-01-20 | |
| 2014-09-30 | $0.00 10-Q · filed 2014-11-12 | |
| 2014-06-30 | $0.00 10-Q · filed 2014-08-12 | |
| 2014-03-31 | $0.00 10-Q · filed 2014-05-13 | |
| 2013-12-31 | $0.00 10-K · filed 2015-03-12 | |
| 2012-12-31 | $0.00 10-K · filed 2014-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |